Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck's Ezetimibe Faces Reimbursement Threat In Europe

This article was originally published in The Pink Sheet Daily

Executive Summary

Results from the ENHANCE and ARBITER 6-HALTS trials may finally mean reduced coverage in Germany and the U.K.
Advertisement

Related Content

European HTA: Cancer Drugs Suffer At NICE, Whilst IQWiG And HAS Also Tighten Purse Strings
Lipitor Will Fade, Not Fall Off The Patent Cliff In Europe
Merck Releases Positive Study For Vytorin, But How Much Impact Will It Have?
Abbott's Niaspan/Zetia Head-To-Head Trial Deemed Too Small And Inconclusive
Vytorin, Zetia Coverage In 2009 Among All Payers Still Solid But Slipping
Vytorin, Zetia Coverage In 2009 Among All Payers Still Solid But Slipping

Topics

Advertisement
UsernamePublicRestriction

Register

PS072333

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel